DaVita (NYSE:DVA – Get Free Report) and Guardant Health (NASDAQ:GH – Get Free Report) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Risk and Volatility
DaVita has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Guardant Health has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500.
Valuation and Earnings
This table compares DaVita and Guardant Health”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DaVita | $13.64 billion | 0.72 | $746.80 million | $13.58 | 11.52 |
| Guardant Health | $982.02 million | 20.06 | -$416.28 million | ($3.68) | -39.56 |
DaVita has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than DaVita, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
90.1% of DaVita shares are held by institutional investors. Comparatively, 92.6% of Guardant Health shares are held by institutional investors. 1.9% of DaVita shares are held by insiders. Comparatively, 5.6% of Guardant Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and recommmendations for DaVita and Guardant Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DaVita | 0 | 3 | 4 | 0 | 2.57 |
| Guardant Health | 1 | 0 | 24 | 1 | 2.96 |
DaVita presently has a consensus target price of $235.86, suggesting a potential upside of 50.72%. Guardant Health has a consensus target price of $190.88, suggesting a potential upside of 31.11%. Given DaVita’s higher probable upside, research analysts plainly believe DaVita is more favorable than Guardant Health.
Profitability
This table compares DaVita and Guardant Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DaVita | 6.49% | -225.93% | 5.42% |
| Guardant Health | -37.93% | N/A | -25.03% |
Summary
Guardant Health beats DaVita on 8 of the 15 factors compared between the two stocks.
About DaVita
DaVita Inc. is a healthcare provider focused on kidney care. Its core business is operating outpatient dialysis centers that provide treatment and related services to people with chronic kidney failure. The company also offers home dialysis programs, provides dialysis services to patients in hospitals, and supports kidney care through services such as care coordination and education. DaVita primarily serves patients in the United States and also operates in international markets. Founded in 1994 as Total Renal Care, the company adopted the name DaVita in 2000.
About Guardant Health
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
